An interventional study of Adaptive Bridging Radiation Therapy (ABRT) in Lymphoma, B-Cell, Relapsed Cancer and Refractory Lymphoma, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.
Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 800th largest by enrollment of the 963 interventional ones that give a count, is one of 28 that started in 2024, is one of 57 with no phase, and was the 1,039th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Nathan Denlinger · Sites in United States
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 542 · Phase 2 537 · Phase 3 82 · Phase 4 2
First in 1988; this study’s year is marked. 28 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 37 across the 963 interventional studies, 84 across the 66 observational. Of the 849 that completed or were terminated, 330 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
314 of 1,131 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 8 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
69 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04442022Phase 3Karyopharm Therapeutics IncA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | 2026-12 |
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT04799275Phase 3National Cancer Institute (NCI)Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | 2027-03-01 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
Add all 69 to your calendar (.ics) → With an account.
Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.
This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy.
In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.
This is a feasibility/pilot study of 5 Gy adaptive radiation administered every 5 business days (1 week apart) for 5 weeks prior to standard of care CAR T-cell therapy infusion. Approximately 10 participants with Relapsed/Refractory B-cell Lymphoma will take part in this research study. The primary objective is to assess the feasibility of once weekly radiation therapy for 5 weeks.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 10 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion
Radiation: Adaptive Bridging Radiation Therapy (ABRT)
Radiation Therapy
Feasibility: Percent of Patients Able to Undergo Once-weekly ABRT
Feasibility is being measured based on the percentage of patients being able to undergo ABRT
Time frame: From initial CBCT acquisition to the end of ABRT treatment (5-9 weeks total).
Adverse Events
Adverse events will be classified and graded according to the CTCAE v.5.0.
Time frame: Adverse events were recorded at enrollment, during treatment at each fraction, and 30 and 90 days post CAR T-cell treatment, up to 25 weeks in total.
In-field Disease Response at 30 and 90 Days Post CAR T-cell Therapy
The time frame of the reported in-field disease response data is the duration of response (DOR). The median DOR for patients with a complete response (CR) was 4.9 months (2.9-6.5 months) and 2.4 months (0.5-7.4 months) for patients with disease progression (DP). Partial response and stable disease were not observed. In-field disease response is assessed using PET/CT with Deauville scoring: CR: compatible with Deauville score of 1-3 on PET/CT PR: compatible with Deauville score of 4-5 on PET/CT, with shrinkage as compared to CT simulation scan SD: compatible with Deauville score of 4-5 on PET/CT, with size stable compared to CT simulation scan DP: compatible with Deauville score of 4-5 on PET/CT, with increase in size compared to CT simulation scan
Time frame: Patients were assessed at 30 and day 90 following CAR T-cell infusion (approximately 11 weeks and 19 weeks post enrollment, respectively). See outcome measure description for details on the time frames of the reported data.
Patients were recruited between January 2024 and May 2024 at Massachusetts General Hospital.
| Milestone | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Feasibility is being measured based on the percentage of patients being able to undergo ABRT
| Participants | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Patients who achieved complete response | 10 |
Adverse events will be classified and graded according to the CTCAE v.5.0.
| Participants | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Cytokine Release Syndrome (gr. 3 or higher) | 0 |
| Immune Effector Cell-Associated Neurotoxicity Syndrome (gr. 3 or higher) | 3 |
The time frame of the reported in-field disease response data is the duration of response (DOR). The median DOR for patients with a complete response (CR) was 4.9 months (2.9-6.5 months) and 2.4 months (0.5-7.4 months) for patients with disease progression (DP). Partial response and stable disease were not observed. In-field disease response is assessed using PET/CT with Deauville scoring: CR: compatible with Deauville score of 1-3 on PET/CT PR: compatible with Deauville score of 4-5 on PET/CT, with shrinkage as compared to CT simulation scan SD: compatible with Deauville score of 4-5 on PET/CT, with size stable compared to CT simulation scan DP: compatible with Deauville score of 4-5 on PET/CT, with increase in size compared to CT simulation scan
| Participants | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Complete Response (CR) | 7 |
| Partial Response (PR) | 0 |
| Stable Disease (SD) | 0 |
| Disease Progression (DP) | 3 |
Collected over From start of ABRT to 90 days post-CAR T Therapy (up to 25 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) | 1/10 (10%) | 0/10 (0%) | 8/10 (80%) |
| Event | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| White blood cell count decreasedBlood and lymphatic system disorders | 4/10 |
| Lymphocyte Count DecreasedBlood and lymphatic system disorders | 4/10 |
| Neutrophil cout decreasedBlood and lymphatic system disorders | 4/10 |
| In-field recurrenceNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/10 |
| Immune effector cell-associated neurotoxicity syndromeImmune system disorders | 3/10 |
| AnemiaBlood and lymphatic system disorders | 3/10 |
| Pelvic painReproductive system and breast disorders | 2/10 |
| LymphedemaVascular disorders | 1/10 |
| ParesthesiaNervous system disorders | 1/10 |
| Spinal cord compressionNervous system disorders | 1/10 |
No difference between Baseline participant count and Participant flow count.
| Age, Continuous(years) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Median | 70 (59 to 84) |
| Sex: Female, Male(Participants) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Female | 7 |
| Male | 3 |
| Race/Ethnicity, Customized(Participants) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Race/Ethnicity — White, Non-Hispanic | 8 |
| Race/Ethnicity — Other, more than one race | 2 |
| Histopathology(Participants) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| DLBCL (diffuse large B-cell lymphoma) | 5 |
| TFL (transformed follicular lymphoma) | 3 |
| HGBCL (high-grade B-cell lymphoma) with MYC and BCL2 oncogene rearrangements | 1 |
| Waldenstrom's macroglobulinemia | 1 |
| Cell of Origin(Participants) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| GCB (Germinal center B-cell) | 4 |
| Non-GCB (Non-Germinal center B-cell) | 6 |
| Stage at time of diagnosis(Participants) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| I | 3 |
| II | 2 |
| IV | 5 |
| Age at the time of diagnosis(Years) | 5-5-5 Adaptive Bridging Radiation Therapy (ABRT) |
|---|---|
| Median | 67 (55 to 74) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation
Ran from Jan 2024 to primary completion in Oct 2024, 8 months.
Results were first posted in Oct 2026, 2 years after primary completion.
Of 40 non-industry interventional studies with no phase under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 144. This study's 8 months is below that.
Counting every sponsor, half of 41 studies reached it within 73 months; a quarter within 42 and three quarters within 137.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Massachusetts General Hospital →